Drugs / LINAVONKIBART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04291079 | Apr 2020 → Apr 2025 | cancer | Scholar Rock, Inc. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2024-06-03 | Scholar Rock, Inc. | Results Scholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting scholarrock.com ↗
The results show encouraging responses in heavily pretreated and anti-PD-(L)1 resistant patients across multiple tumor types. |
| 2024-05-28 | Scholar Rock, Inc. | Results Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting scholarrock.com ↗
We continued to observe encouraging responses and tolerability in heavily pretreated patients across multiple cancer types, providing further evidence of SRK-181’s potential to overcome resistance to immune checkpoint inhibitors,” said Jay Backstrom , M.D., M.P.H., President and Chief Executive Officer of Scholar Rock . |
| 2023-11-03 | Scholar Rock, Inc. | Results Scholar Rock Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients and Supporting SRK-181 Continued Tolerability scholarrock.com ↗
Data presented continues to support proof of concept for SRK-181 in 28 heavily pretreated patients with ccRCC resistant to anti-PD-1. |
| 2022-11-10 | Scholar Rock, Inc. | Results Recent Phase 1 DRAGON Data Show SRK-181 Continues to be Well Tolerated with Early Indications of Efficacy scholarrock.com ↗
Two confirmed partial responses observed in patients with anti-PD-1 resistant clear cell renal cell carcinoma |
| 2021-11-12 | Scholar Rock, Inc. | Results Scholar Rock Presents Data from Part A of the DRAGON Phase 1 Trial Evaluating SRK-181 as Monotherapy and in Combination with Anti-PD-(L)1 for the Treatment of Solid Tumors -- Announces Advancement into Part B scholarrock.com ↗
Safety and pharmacokinetic results from Part A dose escalation supported Part B dose selection, which is estimated to offer drug exposure at levels exceeding those hypothesized as needed for anti-tumor effects |
| 2021-09-28 | Scholar Rock, Inc. | Regulatory Scholar Rock Announces Issuance of U.S. Patent Protecting SRK-181, an Inhibitor of TGFβ1 Activation scholarrock.com ↗ |
| 2020-03-26 | Scholar Rock, Inc. | Results Scholar Rock Announces Publication in Science Translational Medicine of Preclinical Data Detailing a Potent and Selective Inhibitor of TGFβ1 Overcoming Primary Resistance to Checkpoint Inhibition scholarrock.com ↗
Preclinical results demonstrate highly selective inhibition of TGFβ1 activation with SRK-181-mIgG1 overcomes key mechanism of primary resistance to checkpoint inhibition therapy |
| 2019-04-02 | Scholar Rock, Inc. | Results Scholar Rock Presents Additional Preclinical Data Demonstrating a Highly Specific Inhibitor of TGFβ1 Activation Can Render Resistant Solid Tumors Vulnerable to PD1 Blockade and Drive Tumor Regression with Combination Therapy scholarrock.com ↗
The preclinical data demonstrate that treatment with SRK-181-mIgG1, a highly specific inhibitor of TGFβ1 activation, in combination with an anti-PD1 immunotherapy, can drive tumor regression or control, resulting in significant survival benefit compared to anti-PD1 monotherapy. |
All press releases naming this drug 16 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LINAVONKIBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314686 ↗ |
| Known as | SRK-181 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04291079 ↗ |
| Known as | Srt.beta.1-ab3 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314686 ↗ |
| Modality | Monoclonal antibody | “linavonkibart, a first-in-class fully human selective anti-latent TGFβ1 antibody” PMID 41530380 ↗ Jan 2026 |
| Target | TGFB1 | “anti-latent TGFβ1 antibody” PMID 41530380 ↗ Jan 2026 |